USTR Mulls Response To India SC's Glivec Ruling, Pfizer Wants WTO Look
This article was originally published in PharmAsia News
Executive Summary
The U.S. Trade Representative Office said it is considering a response to the India Supreme Court's denial of a patent for Glivec (imatinib), a Novartis blood-cancer drug.